MSP1
MCID: INC034
MIFTS: 16

Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 1 (MSP1)

Categories: Bone diseases, Genetic diseases, Mental diseases

Aliases & Classifications for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

MalaCards integrated aliases for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 1:

Name: Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 1 12
Multisystem Proteinopathy 1 12
Ibmpfd1 12
Msp1 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0111385

Summaries for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Disease Ontology : 12 An inclusion body myopathy with Paget disease of bone and frontotemporal dementia that has material basis in heterozygous mutation in VCP on chromosome 9p13.3.

MalaCards based summary : Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 1, also known as multisystem proteinopathy 1, is related to inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 1 and inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 2. The drugs Amodiaquine and Artesunate have been mentioned in the context of this disorder. Affiliated tissues include bone and lung.

Related Diseases for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Graphical network of the top 20 diseases related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 1:



Diseases related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 1

Symptoms & Phenotypes for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Drugs & Therapeutics for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Drugs for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
2
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
3
Primaquine Approved Phase 4 90-34-6 4908
4
Piperaquine Experimental, Investigational Phase 4 4085-31-8 5079497
5
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483
6 Artemisinins Phase 4
7 Artemisinine Phase 4
8 Antiprotozoal Agents Phase 4
9 Antiparasitic Agents Phase 4
10 Antimalarials Phase 4
11 Anti-Infective Agents Phase 4
12 Antiviral Agents Phase 4
13 Anthelmintics Phase 4
14
Lumefantrine Approved Phase 3 82186-77-4 6437380
15
Artemether Approved Phase 3 71963-77-4 119380 68911
16
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
17
Pyrimethamine Approved, Investigational, Vet_approved Phase 2, Phase 3 58-14-0 4993
18
Sulfadoxine Approved, Investigational Phase 2, Phase 3 2447-57-6 17134
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
20
Lactitol Investigational Phase 3 585-86-4, 585-88-6 493591
21 Artemether, Lumefantrine Drug Combination Phase 3
22 Renal Agents Phase 2, Phase 3
23 Vitamin B Complex Phase 2, Phase 3
24 Folic Acid Antagonists Phase 2, Phase 3
25 Anti-Infective Agents, Urinary Phase 2, Phase 3
26 Vitamin B9 Phase 2, Phase 3
27 Folate Phase 2, Phase 3
28 Vaccines Phase 1, Phase 2
29 Immunologic Factors Phase 1, Phase 2
30
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
31
Neomycin Approved, Vet_approved Phase 1 1404-04-2 8378
32 Gastrointestinal Agents Phase 1
33 Adjuvants, Immunologic Phase 1
34 Anti-Ulcer Agents Phase 1
35 Antacids Phase 1
36 Fanasil, pyrimethamine drug combination
37 Amodiaquine, artesunate drug combination

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
2 Efficacy and Safety of Artesunate + Amodiaquine Combined With a Single Low Dose of Primaquine (0.25 mg/kg) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Zanzibar Completed NCT03773536 Phase 4 Artesunate-amodiaquine given with single low dose primaquine
3 Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya Unknown status NCT01899820 Phase 3 Artemether lumefantrine;Dihydroartemisinin piperaquine
4 An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar Completed NCT02020330 Phase 3 Artemether-lumefantrine 3 days;Artemether-lumefantrine 5 days
5 Anti-malarial Drug Resistance in Cameroon: Therapeutic Efficacy and Biological Markers of Resistance Completed NCT00146718 Phase 2, Phase 3 Amodiaquine and Sulphadoxine/Pyrimethamine
6 Phase III Clinical Trials of Artemisinin-based Combination Therapy in Cameroon Completed NCT00297882 Phase 3 Artemether-Lumefantrine , Amodiaquine-Artesunate
7 A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP Completed NCT01142765 Phase 1, Phase 2
8 A Phase I/IIa Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates AdCh63 MSP1 Alone and With MVA MSP1 Completed NCT01003314 Phase 1, Phase 2
9 Phase 1 Study of the Safety and Immunogenicity of MSP1 42-C1/Alhydrogel With and Without CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria Completed NCT00320658 Phase 1
10 Phase 1 Study of the Safety and Immunogenicity of MSP1(42)-FVO/Alhydrogel and MSP1(42)-3D7/Alhydrogel, Asexual Blood-Stage Vaccines for Plasmodium Falciparum Malaria Completed NCT00340431 Phase 1 MSP1(42)-FVO & MSP1(42)-3D7
11 A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP Alone and With MVA PvDBP Completed NCT01816113 Phase 1
12 Double Blind Randomized Controlled Phase I Trial to Evaluate the Safety and Immunogenicity of WRAIR's MSP1 Candidate Malaria Vaccine (FMP1) Adjuvant in GSK Bio's AS02A vs. Rabies Vaccine in Semi-immune Adults in Bandiagara, Mali. Completed NCT00308061 Phase 1
13 Phase 1 Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and in Bancoumana, Mali Completed NCT00889616 Phase 1 BSAM2/Alhydrogel + CPG 7909
14 Efficacy and Safety of Artesunate+Sulphadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Center Asadabad in Kunar Province of Afghanistan Unknown status NCT01707199 Artesunate + Sulphadoxine-pyrimethamine
15 Fetal Immunity to Plasmodium Falciparum Malaria Completed NCT00314899
16 Efficacy of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Pweto, Democratic Republic of Congo, 2008 Completed NCT01567423 ASAQ Winthrop® Sanofi Aventis;Coartem®, Novartis

Search NIH Clinical Center for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 1

Genetic Tests for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Anatomical Context for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

MalaCards organs/tissues related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 1:

40
Bone, Lung

Publications for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Articles related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 1:

# Title Authors PMID Year
1
Interaction between the AAA+ ATPase p97 and its cofactor ataxin3 in health and disease: Nucleotide-induced conformational changes regulate cofactor binding. 61
28939772 2017
2
p97 Disease Mutations Modulate Nucleotide-Induced Conformation to Alter Protein-Protein Interactions. 61
27267671 2016

Variations for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Expression for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Search GEO for disease gene expression data for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 1.

Pathways for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

GO Terms for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Sources for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....